Objective The aim of this study was to assess the value of palliative local treatment of incurable metastatic lesions in colorectal cancer(CRC) patients receiving chemotherapy plus bevacizumab.Methods Data of 105 pati...Objective The aim of this study was to assess the value of palliative local treatment of incurable metastatic lesions in colorectal cancer(CRC) patients receiving chemotherapy plus bevacizumab.Methods Data of 105 patients with histologically confirmed synchronous or metachronous metastatic CRC who received bevacizumab treatment from January 1, 2011 to January 31, 2017 were retrospectively reviewed. Sixteen(15%) patients who were treated with bevacizumab for less than 4 cycles were excluded, and finally, 89(85%) patients were enrolled. Among them, 33(37%) patients who received palliative local treatment were categorized into the palliative local treatment group, and the remaining 56(63%) patients were categorized into the chemotherapy plus bevacizumab group. The primary endpoint was overall survival(OS), which was calculated using Kaplan-Meier survival analyses. Factors possibly influencing survival were evaluated by univariate and multivariate analyses. Adverse events(AEs) were graded according to Common Terminology Criteria for Adverse Events, version 4.0. Grades 1–2 and 3–4 AEs of the two groups were compared and analyzed using the Fisher's exact test and χ~2 analysis.Results The median follow-up period was 20.4 months, ranging from 1 to 60 months. The median OS in the palliative local treatment group was 36.3 months(95% CI, 33.5–39.2), and that in the chemotherapy plus bevacizumab group was 20.5 months(95% CI, 17.6–23.4). Both the univariate(HR 0.13, 95% CI, 0.05–0.30, P < 0.001) and multivariate(HR 0.16, 95% CI, 0.07–0.39, P < 0.001) analyses showed that the addition of palliative local treatment could prolong survival compared with chemotherapy plus bevacizumab alone. There were no significant differences in the rates of common chemotherapy-or bevacizumab-related AEs between the two groups.Conclusion These findings suggest palliative local treatment is an effective and safe method for treating patients with incurable metastatic CRC receiving chemotherapy plus bevacizumab.展开更多
Zinc oxide(ZnO)thin film as a piezoelectric material for microelectromechanical system(MEMS)actuators and sensors was evaluated.ZnO thin films were deposited using radio frequency(RF)magnetron sputtering.Process param...Zinc oxide(ZnO)thin film as a piezoelectric material for microelectromechanical system(MEMS)actuators and sensors was evaluated.ZnO thin films were deposited using radio frequency(RF)magnetron sputtering.Process parameters such as gas ratio,working pressure,and RF power were optimized for crystalline structure.The ZnO thin films were characterized by X-ray diffraction(XRD)and scanning electron microscopy(SEM).Good quality of ZnO thin films was further confirmed by a high transverse piezoelectric coefficient d31.A microcantilever was then designed,fabricated,and characterized.Design formulas of resonant frequency,actuation,and sensing sensitivities were derived.The resonant frequency was determined by an impedance analyzer.Tip deflection on nanometer level was demonstrated with the cantilever used as an actuator.The actuation sensitivity was found to be 12.2 nm/V.As a sensor,the cantilever was calibrated against a reference accelerometer.The sensing sensitivity was characterized to be 46 mV/g.The characterization results were compared with design specifications.The differences were caused mainly by thickness control in etching.This study showed that ZnO is a promising piezoelectric material for MEMS actuators and sensors in terms of excellent process compatibility and good piezoelectric performance.展开更多
文摘Objective The aim of this study was to assess the value of palliative local treatment of incurable metastatic lesions in colorectal cancer(CRC) patients receiving chemotherapy plus bevacizumab.Methods Data of 105 patients with histologically confirmed synchronous or metachronous metastatic CRC who received bevacizumab treatment from January 1, 2011 to January 31, 2017 were retrospectively reviewed. Sixteen(15%) patients who were treated with bevacizumab for less than 4 cycles were excluded, and finally, 89(85%) patients were enrolled. Among them, 33(37%) patients who received palliative local treatment were categorized into the palliative local treatment group, and the remaining 56(63%) patients were categorized into the chemotherapy plus bevacizumab group. The primary endpoint was overall survival(OS), which was calculated using Kaplan-Meier survival analyses. Factors possibly influencing survival were evaluated by univariate and multivariate analyses. Adverse events(AEs) were graded according to Common Terminology Criteria for Adverse Events, version 4.0. Grades 1–2 and 3–4 AEs of the two groups were compared and analyzed using the Fisher's exact test and χ~2 analysis.Results The median follow-up period was 20.4 months, ranging from 1 to 60 months. The median OS in the palliative local treatment group was 36.3 months(95% CI, 33.5–39.2), and that in the chemotherapy plus bevacizumab group was 20.5 months(95% CI, 17.6–23.4). Both the univariate(HR 0.13, 95% CI, 0.05–0.30, P < 0.001) and multivariate(HR 0.16, 95% CI, 0.07–0.39, P < 0.001) analyses showed that the addition of palliative local treatment could prolong survival compared with chemotherapy plus bevacizumab alone. There were no significant differences in the rates of common chemotherapy-or bevacizumab-related AEs between the two groups.Conclusion These findings suggest palliative local treatment is an effective and safe method for treating patients with incurable metastatic CRC receiving chemotherapy plus bevacizumab.
文摘Zinc oxide(ZnO)thin film as a piezoelectric material for microelectromechanical system(MEMS)actuators and sensors was evaluated.ZnO thin films were deposited using radio frequency(RF)magnetron sputtering.Process parameters such as gas ratio,working pressure,and RF power were optimized for crystalline structure.The ZnO thin films were characterized by X-ray diffraction(XRD)and scanning electron microscopy(SEM).Good quality of ZnO thin films was further confirmed by a high transverse piezoelectric coefficient d31.A microcantilever was then designed,fabricated,and characterized.Design formulas of resonant frequency,actuation,and sensing sensitivities were derived.The resonant frequency was determined by an impedance analyzer.Tip deflection on nanometer level was demonstrated with the cantilever used as an actuator.The actuation sensitivity was found to be 12.2 nm/V.As a sensor,the cantilever was calibrated against a reference accelerometer.The sensing sensitivity was characterized to be 46 mV/g.The characterization results were compared with design specifications.The differences were caused mainly by thickness control in etching.This study showed that ZnO is a promising piezoelectric material for MEMS actuators and sensors in terms of excellent process compatibility and good piezoelectric performance.